When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Brian Shuch, MD, director of the UCLA Kidney Cancer Program, explains what to expect after a radical nephrectomy. The procedure can be done minimally invasively, either laparoscopically or robotically,…
Heather N. Reich, MD, CM, PhD, FRCPC, Oreopoulos-Baxter Division Director of Nephrology, University of Toronto, discusses translating new clinical trials in IgA nephropathy, a kidney disease. Dr Reich…
Diana Girnita, MD, PhD, founder of Rheumatologist OnCall, discusses who should exercise, when to exercise, and where to exercise. Melissa Koehl, PT, DPT, introduces the 10 best exercises…
